-Reuters
Pfizer Stock Pops: Study Shows Company’s Oral Weight Loss Drug Could Be As Effective As Novo Nordic’s Ozempic Injection
Pfizer Inc (NYSE: PFE) shares are trading higher Monday in the wake of a newly released study suggesting the company's oral weight loss drug may be as effective as Novo Nordisk's (NYSE: NVO)